[go: up one dir, main page]

CY1122466T1 - Σκευασμα αντισωματος αντι il-17ra και θεραπευτικα σχηματα για την αγωγη της ψωριασης - Google Patents

Σκευασμα αντισωματος αντι il-17ra και θεραπευτικα σχηματα για την αγωγη της ψωριασης

Info

Publication number
CY1122466T1
CY1122466T1 CY20191101143T CY191101143T CY1122466T1 CY 1122466 T1 CY1122466 T1 CY 1122466T1 CY 20191101143 T CY20191101143 T CY 20191101143T CY 191101143 T CY191101143 T CY 191101143T CY 1122466 T1 CY1122466 T1 CY 1122466T1
Authority
CY
Cyprus
Prior art keywords
treatment
psoriasis
antibody formulation
therapeutic forms
therapeutic
Prior art date
Application number
CY20191101143T
Other languages
English (en)
Inventor
Dingjiang Liu
Holly Zhuohong Huang
David Andrew Martin
Christopher Boyd Russell
David H. Salinger
Scott Walter Baumgartner
Christopher J. Endres
Original Assignee
Kirin-Amgen, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43858045&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1122466(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kirin-Amgen, Inc. filed Critical Kirin-Amgen, Inc.
Publication of CY1122466T1 publication Critical patent/CY1122466T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)

Abstract

Η παρούσα αποκάλυψη σχετίζεται με ΑΜ-14 φαρμακευτικά σκευάσματα και θεραπευτικά σχήματα δοσολόγησης για την αγωγή πάθησης.
CY20191101143T 2010-01-15 2019-11-04 Σκευασμα αντισωματος αντι il-17ra και θεραπευτικα σχηματα για την αγωγη της ψωριασης CY1122466T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US29538710P 2010-01-15 2010-01-15
US42205910P 2010-12-10 2010-12-10
PCT/US2011/020985 WO2011088120A1 (en) 2010-01-15 2011-01-12 Antibody formulation and therapeutic regimens
EP11705713.3A EP2523688B1 (en) 2010-01-15 2011-01-12 Antibody formulation and therapeutic regimens

Publications (1)

Publication Number Publication Date
CY1122466T1 true CY1122466T1 (el) 2020-10-14

Family

ID=43858045

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20181100022T CY1119852T1 (el) 2010-01-15 2018-01-09 Σκευασμα αντισωματος και θεραπευτικα σχηματα
CY20191101143T CY1122466T1 (el) 2010-01-15 2019-11-04 Σκευασμα αντισωματος αντι il-17ra και θεραπευτικα σχηματα για την αγωγη της ψωριασης

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20181100022T CY1119852T1 (el) 2010-01-15 2018-01-09 Σκευασμα αντισωματος και θεραπευτικα σχηματα

Country Status (38)

Country Link
US (5) US8883151B2 (el)
EP (3) EP3295957B1 (el)
JP (2) JP5743234B2 (el)
KR (1) KR101766936B1 (el)
CN (1) CN102821787B (el)
AR (1) AR079903A1 (el)
AU (3) AU2011205402B2 (el)
BR (1) BR112012017150B1 (el)
CA (1) CA2787128C (el)
CL (1) CL2012001966A1 (el)
CO (1) CO6640206A2 (el)
CR (1) CR20120419A (el)
CY (2) CY1119852T1 (el)
DK (2) DK3295957T3 (el)
EA (2) EA031209B9 (el)
ES (2) ES2652637T3 (el)
HR (1) HRP20171939T1 (el)
HU (2) HUE046670T2 (el)
IL (1) IL220602B (el)
IN (1) IN2012DN06720A (el)
LT (2) LT2523688T (el)
MA (1) MA33989B1 (el)
MX (1) MX349856B (el)
MY (1) MY182680A (el)
NO (1) NO2523688T3 (el)
NZ (1) NZ601125A (el)
PE (1) PE20121691A1 (el)
PH (1) PH12012501364A1 (el)
PL (2) PL3295957T3 (el)
PT (2) PT3295957T (el)
RS (2) RS59743B1 (el)
SG (2) SG10201604093XA (el)
SI (2) SI2523688T1 (el)
TN (1) TN2012000335A1 (el)
TW (1) TWI554282B (el)
UA (1) UA112288C2 (el)
WO (1) WO2011088120A1 (el)
ZA (1) ZA201205167B (el)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
SG10201604093XA (en) 2010-01-15 2016-07-28 Kirin Amgen Inc Antibody formulation and therapeutic regimens
ES2716088T3 (es) 2010-02-04 2019-06-10 Csl Behring Ag Preparado de inmunoglobulina
CA2791951C (en) 2010-05-20 2019-05-14 Ablynx Nv Biological materials related to her3
JP6159660B2 (ja) * 2010-09-22 2017-07-05 アムジエン・インコーポレーテツド 担体としての免疫グロブリンおよびその使用
WO2012138958A1 (en) * 2011-04-07 2012-10-11 Glaxosmithkline Llc Formulations with reduced viscosity
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
JOP20200043A1 (ar) * 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
WO2013016220A1 (en) * 2011-07-22 2013-01-31 Amgen Inc. Il-17 receptor a is required for il-17c biology
JP6203740B2 (ja) * 2011-11-23 2017-09-27 アムジェン インコーポレイテッド アルファ４ベータ７ヘテロ二量体特異抗体の投与
KR101653082B1 (ko) * 2012-03-07 2016-08-31 일라이 릴리 앤드 캄파니 Il-17 항체 제제
MX2014013508A (es) 2012-05-14 2015-02-10 Novo Nordisk As Soluciones proteinicas estabilizadas.
SG10201805015TA (en) 2013-03-15 2018-07-30 Amgen Inc Methods for treating crohn's disease using an anti-il23 antibody
EA201591581A1 (ru) 2013-03-15 2016-01-29 Амген Инк. Способы лечения псориаза при помощи анти-il-23 антитела
KR102530900B1 (ko) * 2014-03-31 2023-05-12 암젠 케이-에이, 인크. 손발톱 및 두피 건선의 치료 방법
MX2016014761A (es) 2014-05-16 2017-05-25 Amgen Inc Ensayo para detectar poblaciones celulares linfocitos t colaboradores 1 (th1) y linfocitos t colaboradores (th2).
EP3185902B1 (en) 2014-08-26 2020-07-29 Amgen K-A, Inc. Method for treating psoriasis patient which received anti-tnf-alpha antibody therapy
JP6795397B2 (ja) * 2014-09-10 2020-12-02 日油株式会社 蛋白質吸着抑制剤及び蛋白質吸着抑制方法
HUE069126T2 (hu) 2014-12-03 2025-02-28 Csl Behring Ag Immunoglobulinokat tartalmazó megnövelt stabilitású gyógyszerészeti termék
EP3349854A4 (en) 2015-09-17 2019-04-03 Amgen Inc. PREDICTING THE CLINICAL RESPONSE TO IL23 ANTAGONISTS WITH IL23 PATIENT BIOMARKERS
AU2016349113A1 (en) 2015-11-04 2018-06-07 Astrazeneca Ab Dipeptidyl peptidase-4 and periostin as predictors of clinical response to eosinophil-targeted therapeutic agents in eosinophilic diseases
CA3007098A1 (en) 2015-12-22 2017-06-29 Amgen Inc Ccl20 as a predictor of clinical response to il23-antagonists
JP6694522B2 (ja) 2016-04-19 2020-05-13 セイジ・エレクトロクロミクス，インコーポレイテッド 透明導電性酸化物層及びバスバーを含むエレクトロクロミックデバイス、ならびにその形成プロセス
GB201612043D0 (en) * 2016-07-11 2016-08-24 Crescendo Biologics Ltd Composition for treatment of disorders
CA2974531A1 (en) * 2017-07-26 2019-01-26 Michael Giroux Safety anchor and roof vent
GB201719447D0 (en) 2017-11-23 2018-01-10 Ucb Biopharma Sprl Pharmaceutical composition
EA202190197A1 (ru) 2018-07-13 2021-04-26 Астразенека Коллаборэйшн Венчерз, Ллс Лечение язвенного колита с помощью бразикумаба
BR112021015034A2 (pt) 2019-02-18 2021-10-05 Eli Lilly And Company Formulação de anticorpo terapêutico
WO2021050563A1 (en) * 2019-09-09 2021-03-18 The Rockefeller University Antibody treatment for lesional tissue of hidradenitis suppurativa
CN114401993A (zh) 2019-09-11 2022-04-26 博世健康爱尔兰有限公司 使用il-17ra抗体治疗非酒精性脂肪肝疾病(nafld)的方法
CN112891530B (zh) * 2020-06-19 2021-08-24 北京东方百泰生物科技股份有限公司 一种抗il-17ra单克隆抗体的注射制剂
EP4337257A1 (en) * 2021-05-12 2024-03-20 AnaptysBio, Inc. Antibody composition
WO2023240071A1 (en) * 2022-06-06 2023-12-14 Fusion Pharmaceuticals Inc. Methods of dosing therapeutic agents

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1000835A (en) 1911-06-19 1911-08-15 Stewart A Minnick Calipers.
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
IL83878A (en) 1987-09-13 1995-07-31 Yeda Res & Dev Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
IL98078A0 (en) 1991-05-07 1992-06-21 Yeda Res & Dev Pharmaceutical compositions comprising an anticytokyne
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
GB8807803D0 (en) 1988-03-31 1988-05-05 Glaxo Group Ltd Biochemical product
EP0362371A4 (en) 1988-04-15 1990-10-24 Protein Design Labs, Inc. Il-2 receptor-specific chimeric antibodies
IL94039A (en) 1989-08-06 2006-09-05 Yeda Res & Dev Antibodies to tbp - 1 and their use
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
ATE289350T1 (de) 1989-04-21 2005-03-15 Amgen Inc Tnf-rezeptor, tnf bindende proteine und dafür kodierende dnas
DE3922089A1 (de) 1989-05-09 1990-12-13 Basf Ag Neue proteine und ihre herstellung
EP0398327B2 (en) 1989-05-18 2013-02-20 Yeda Research And Development Co., Ltd. Tumor necrosis factor binding protein II, its purification and antibodies thereto
IL95031A (en) 1989-07-18 2007-03-08 Amgen Inc A method of producing a recombinant human necrotic factor absorber
US5703088A (en) 1989-08-21 1997-12-30 Beth Israel Deaconess Medical Center, Inc. Topical application of spiperone or derivatives thereof for treatment of pathological conditions associated with immune responses
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
CA2485553A1 (en) 1989-09-05 1991-03-21 Immunex Corporation Tumor necrosis factor - .alpha. and - .beta. receptors
DE59010933D1 (de) 1989-09-12 2003-05-08 Hoffmann La Roche TFN-bindende Proteine
JPH03127800A (ja) 1989-10-13 1991-05-30 Teijin Ltd 腫瘍壊死因子活性抑制物質
AU642938B2 (en) 1989-12-13 1993-11-04 Yeda Research And Development Co. Ltd. Expression of the recombinant tumor necrosis factor binding protein 1 (TBP-1)
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
WO1991010741A1 (en) 1990-01-12 1991-07-25 Cell Genesys, Inc. Generation of xenogeneic antibodies
US5136021A (en) 1990-02-27 1992-08-04 Health Research, Inc. TNF-inhibitory protein and a method of production
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US6458360B1 (en) 1990-04-25 2002-10-01 The Johns Hopkins University Soluble complement regulatory molecules
GB2243569A (en) 1990-05-02 1991-11-06 Andrew Langdon Brush with timer
EP0835939B8 (de) 1990-06-28 2006-01-11 Sanofi-Aventis Deutschland GmbH Fusionsproteine mit Immunglobulinanteilen, ihre Herstellung und Verwendung
WO1992001002A1 (fr) 1990-07-11 1992-01-23 Teijin Limited Inhibiteur de l'activite du facteur de la necrose tumorale et son procede de preparation
KR100234520B1 (ko) 1991-01-18 1999-12-15 그레고리 아보트 종양괴사인자 매개병 치료용 의약품 조성물
SG89295A1 (en) 1991-03-15 2002-06-18 Amgen Inc Pegylation of polypeptides
IL99120A0 (en) 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
JP3122139B2 (ja) 1991-10-15 2001-01-09 マラーキー，ミッシェル，エフ． 後期段階炎症反応の治療用組成物
US5716805A (en) 1991-10-25 1998-02-10 Immunex Corporation Methods of preparing soluble, oligomeric proteins
ATE297465T1 (de) 1991-11-25 2005-06-15 Enzon Inc Verfahren zur herstellung von multivalenten antigenbindenden proteinen
AU671116B2 (en) 1992-03-30 1996-08-15 Immunex Corporation Fusion proteins comprising tumor necrosis factor receptor
EP0639079B1 (en) 1992-04-30 2000-01-12 Amgen Inc. Methods for treating interleukin-1 and tumor necrosis factor mediated diseases
JPH05312248A (ja) 1992-05-08 1993-11-22 Nissan Motor Co Ltd シフトレバー装置
NZ256293A (en) 1992-09-15 1997-06-24 Immunex Corp Method of treating tumour necrosis factor - mediated inflammation by use of tnf antagonist
WO1994013804A1 (en) 1992-12-04 1994-06-23 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
US6562333B1 (en) 1993-06-14 2003-05-13 Schering Corporation Purified mammalian CTLA-8 antigens and related reagents
US6680057B1 (en) 1995-03-23 2004-01-20 Immunex Corporation Methods of treating autoimmune disease by administering interleukin-17 receptor
JP4373495B2 (ja) 1995-03-23 2009-11-25 イミュネックス・コーポレーション Ｉｌ−１７受容体
PT839196E (pt) 1995-07-19 2005-09-30 Inst Genetics Llc Ctla-8 humana e utilizacoes de proteinas relacionadas com ctla-8
US6074849A (en) 1995-07-19 2000-06-13 Genetics Institute, Inc. Polynucleotides encoding human CTLA-8 related proteins
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
US6406867B1 (en) 1996-08-16 2002-06-18 Human Genome Sciences, Inc. Antibody to human endokine alpha and methods of use
JP2001506982A (ja) 1996-11-27 2001-05-29 イミュネックス・コーポレーション 一酸化窒素産生の制御法
EP2305027B1 (en) 1996-12-03 2014-07-02 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6482923B1 (en) 1997-09-17 2002-11-19 Human Genome Sciences, Inc. Interleukin 17-like receptor protein
US6635443B1 (en) 1997-09-17 2003-10-21 Human Genome Sciences, Inc. Polynucleotides encoding a novel interleukin receptor termed interleukin-17 receptor-like protein
EP1076703B2 (en) 1998-05-15 2010-12-15 Genentech, Inc. Therapeutic uses of il-17 homologous polypeptides
JP2000247903A (ja) * 1999-03-01 2000-09-12 Chugai Pharmaceut Co Ltd 長期安定化製剤
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
IL149008A0 (en) 1999-10-04 2002-11-10 Chiron Corp Stabilized liquid polypeptide-containing pharmaceutical compositions
AR030554A1 (es) 2000-03-16 2003-08-27 Amgen Inc Moleculas similares a receptores il-17 y usos de las mismas
AR028256A1 (es) 2000-03-16 2003-04-30 Amgen Inc Moleculas similares a receptores il-17 y usos de las mismas
US20030180255A1 (en) 2000-08-24 2003-09-25 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
MXPA03003407A (es) 2000-10-18 2004-05-04 Immunex Corp Metodos para el tratamiento de artritis reumatoide usando antagonistas il-17.
JP4583762B2 (ja) 2002-02-27 2010-11-17 イミュネックス・コーポレーション ポリペプチド製剤
US20050153880A1 (en) 2002-06-27 2005-07-14 Yukio Goto Methods of treating or preventing ibd with il-18
DE60305919T2 (de) 2002-06-28 2007-01-18 Domantis Limited, Cambridge Dual-specifische liganden mit erhöhter halbwertszeit
DE10333317A1 (de) 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
US8221771B2 (en) 2003-08-05 2012-07-17 3M Innovative Properties Company Formulations containing an immune response modifier
GB0321703D0 (en) * 2003-09-16 2003-10-15 Imerys Minerals Ltd Surface modified fillers for polymer resin compositions
US20070184050A1 (en) 2003-12-25 2007-08-09 Kirin Beer Kabushiki Kaisha Stable water-based medicinal preparation containing antibody
IL159670A0 (en) 2003-12-31 2004-06-01 Yeda Res & Dev Use of il-18 binding protein in inflammations
KR20070085199A (ko) 2004-06-04 2007-08-27 디자이너 몰레큘스 인코퍼레이티드 자유-라디칼에 경화되는 폴리에스테르 및 그 사용 방법
GB0425569D0 (en) 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
CA2596986A1 (en) 2005-02-14 2006-08-24 Wyeth Use of il-17f in diagnosis and therapy of airway inflammation
WO2006138181A2 (en) 2005-06-14 2006-12-28 Amgen Inc. Self-buffering protein formulations
AU2006278573A1 (en) 2005-08-03 2007-02-15 Immunogen, Inc. Immunoconjugate formulations
AU2006295340B2 (en) 2005-08-05 2010-11-11 Amgen Inc. Stable aqueous protein or antibody pharmaceutical formulations and their preparation
ES2333260T3 (es) 2005-09-01 2010-02-18 Schering Corporation Uso de antagonistas de il-23 e il-17 para tratar la enfermedad inflamatoria ocular autoinmunologica.
CA2624763A1 (en) 2005-10-18 2007-04-26 Zymogenetics, Inc. Il-17c antagonists and methods of using the same
PE20070714A1 (es) 2005-11-01 2007-07-20 Wyeth Corp Solucion de cloruro de sodio para reconstitucion o dilucion de farmaco
JP5231810B2 (ja) * 2005-12-28 2013-07-10 中外製薬株式会社 抗体含有安定化製剤
US20080071063A1 (en) * 2006-02-03 2008-03-20 Medimmune, Inc. Protein Formulations
UA99716C2 (ru) * 2006-10-02 2012-09-25 Кирин-Амген Инк. Антитело, которое специфично связывает человеческий il-17 рецептор а (il-17ra)
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
CA2666842A1 (en) 2006-10-18 2008-04-24 Zymogenetics, Inc. Il-17c antagonists and methods of using the same
FR2910324B1 (fr) 2006-12-21 2009-03-06 Biomerieux Sa Nouveau medicament pour le traitement d'un cancer gastrique
CA2790018C (en) * 2006-12-21 2015-02-03 Amgen Inc. Formulations
GB0700523D0 (en) 2007-01-11 2007-02-21 Insense Ltd The Stabilisation Of Proteins
WO2008118930A1 (en) 2007-03-26 2008-10-02 Zymogenetics, Inc. Soluble il-17ra/rc fusion proteins and related methods
EP2170958A1 (en) 2007-06-13 2010-04-07 Amgen Inc. Il-17 heteromeric receptor complex
WO2009006301A2 (en) 2007-06-29 2009-01-08 Battelle Memorial Institute Protein stabilization
WO2009026122A1 (en) 2007-08-17 2009-02-26 Amgen Inc. Formulations of antibodies and fc-fusion molecules using polycations
WO2009136976A2 (en) 2008-02-21 2009-11-12 Amgen Inc Il-17ra-il-17rb antagonists and uses thereof
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
SG10201604093XA (en) 2010-01-15 2016-07-28 Kirin Amgen Inc Antibody formulation and therapeutic regimens
RU2591083C2 (ru) 2010-10-08 2016-07-10 Новартис Аг Способы лечения псориаза с использованием антагонистов il-17
EP2633317A1 (en) 2010-10-25 2013-09-04 Genentech, Inc. Treatment of gastrointestinal inflammation and psoriasis a
JP2014510152A (ja) * 2011-04-07 2014-04-24 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 粘度が低減された処方物
WO2012138958A1 (en) * 2011-04-07 2012-10-11 Glaxosmithkline Llc Formulations with reduced viscosity
WO2013016220A1 (en) 2011-07-22 2013-01-31 Amgen Inc. Il-17 receptor a is required for il-17c biology
KR102530900B1 (ko) 2014-03-31 2023-05-12 암젠 케이-에이, 인크. 손발톱 및 두피 건선의 치료 방법
EP3185902B1 (en) 2014-08-26 2020-07-29 Amgen K-A, Inc. Method for treating psoriasis patient which received anti-tnf-alpha antibody therapy

Also Published As

Publication number Publication date
WO2011088120A1 (en) 2011-07-21
US20200399384A1 (en) 2020-12-24
NZ601125A (en) 2014-08-29
EP3295957A1 (en) 2018-03-21
JP2015052017A (ja) 2015-03-19
AU2015202023B2 (en) 2017-05-18
RS56781B1 (sr) 2018-04-30
TN2012000335A1 (en) 2013-12-12
CN102821787B (zh) 2015-07-29
LT2523688T (lt) 2018-03-12
PH12012501364A1 (en) 2012-10-22
BR112012017150A2 (pt) 2017-10-10
CA2787128C (en) 2019-06-11
CY1119852T1 (el) 2018-06-27
EP3295957B1 (en) 2019-08-07
AU2011205402B2 (en) 2015-02-05
AU2015202023A1 (en) 2015-05-14
DK2523688T3 (en) 2017-12-04
AR079903A1 (es) 2012-02-29
US10072085B2 (en) 2018-09-11
AU2017216579A1 (en) 2017-09-07
MY182680A (en) 2021-01-29
EA201290653A1 (ru) 2013-02-28
HUE035618T2 (en) 2018-05-28
US8883151B2 (en) 2014-11-11
PL3295957T3 (pl) 2020-03-31
NO2523688T3 (el) 2018-03-10
SI2523688T1 (en) 2018-03-30
US20130022621A1 (en) 2013-01-24
CR20120419A (es) 2012-11-29
BR112012017150B1 (pt) 2022-03-03
SG182468A1 (en) 2012-08-30
IL220602B (en) 2019-03-31
WO2011088120A9 (en) 2012-08-09
US20150017184A1 (en) 2015-01-15
TW201129382A (en) 2011-09-01
DK3295957T3 (da) 2019-10-14
US20230192873A1 (en) 2023-06-22
ZA201205167B (en) 2013-03-27
PL2523688T3 (pl) 2018-04-30
SI3295957T1 (sl) 2020-02-28
TWI554282B (zh) 2016-10-21
JP2013517277A (ja) 2013-05-16
AU2011205402A1 (en) 2012-07-12
HUE046670T2 (hu) 2020-03-30
RS59743B1 (sr) 2020-02-28
US20180346583A1 (en) 2018-12-06
CO6640206A2 (es) 2013-03-22
CL2012001966A1 (es) 2013-01-18
PE20121691A1 (es) 2012-12-14
KR20120118036A (ko) 2012-10-25
MX2012008213A (es) 2012-11-06
ES2753216T3 (es) 2020-04-07
LT3295957T (lt) 2020-01-27
IN2012DN06720A (el) 2015-10-23
EA031209B9 (ru) 2021-11-19
EP3632466A1 (en) 2020-04-08
CA2787128A1 (en) 2011-07-21
MA33989B1 (fr) 2013-02-01
US11505612B2 (en) 2022-11-22
US10808033B2 (en) 2020-10-20
SG10201604093XA (en) 2016-07-28
PT2523688T (pt) 2018-01-05
EA201891433A3 (ru) 2019-02-28
UA112288C2 (uk) 2016-08-25
KR101766936B1 (ko) 2017-08-09
WO2011088120A8 (en) 2012-09-13
HRP20171939T1 (hr) 2018-03-23
EA031209B1 (ru) 2018-12-28
CN102821787A (zh) 2012-12-12
EP2523688A1 (en) 2012-11-21
JP5743234B2 (ja) 2015-07-01
MX349856B (es) 2017-08-16
EP2523688B1 (en) 2017-10-11
EA201891433A2 (ru) 2018-11-30
ES2652637T3 (es) 2018-02-05
PT3295957T (pt) 2019-11-12

Similar Documents

Publication Publication Date Title
CY1122466T1 (el) Σκευασμα αντισωματος αντι il-17ra και θεραπευτικα σχηματα για την αγωγη της ψωριασης
CY1124436T1 (el) Δικυκλικες ετεροκυκλικες ενωσεις και χρησεις αυτων στη θεραπεια
CY1124928T1 (el) Αναστολεις πυραζολυλο κινοξαλινο κινασης
CY1124000T1 (el) Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες σε κρυσταλλικη μορφη
CY1123476T1 (el) Τροποποιητες πυρηνικης μεταφορας και χρησεις αυτων
CY1120429T1 (el) Παραγωγα κιναζολινης για τη θεραπευτικη αντιμετωπιση ιογενων λοιμωξεων και αλλων νοσων
CY1121150T1 (el) Νευροδραστικα 19-αλκοξυ-17-υποκατεστημενα στεροειδη, χρησιμα σε μεθοδους θεραπειας
CY1117372T1 (el) Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες και η χρηση τους
CY1119616T1 (el) Συζευγματα ανθρωπινου αντισωματος-φαρμακου κατα του ιστικου παραγοντα
CY1119200T1 (el) Νεα παραγωγα βενζιμιδαζολιου ως ερ4 ανταγωνιστες
CY1118813T1 (el) Φαρμακευτικες συνθεσεις συν-κρυσταλλων τραμαδολης και κοξιμπων
EA201991484A1 (ru) Лекарственные формы энзалутамида
CY1121538T1 (el) Μονοκλωνικα αντισωματα εναντι του αναστολεα του μονοπατιου ιστικου παραγοντα (tfpi)
EA201300558A1 (ru) Соединения и способы для купирования боли
CY1119410T1 (el) Βελτιστοποιημενα μονοκλωνικα αντισωματα εναντι του αναστολεα της οδου του ιστικου παραγοντα (tfpi)
EA201590343A1 (ru) Алкилпиримидиновые производные для лечения вирусных инфекций и дальнейших заболеваний
CY1120008T1 (el) Βενζαμιδια
EA201590667A1 (ru) Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний
CY1112758T1 (el) Καινοτομοι ανταγωνιστες p2x7r και η χρηση τους
EA201591133A1 (ru) СОСТАВЫ В ВИДЕ РАСТВОРА СКОНСТРУИРОВАННЫХ АНТИТЕЛ К IL-23p19
CY1117785T1 (el) Αναστολεας φωσφοϊνοσιτιδιου 3-κινασης με ενα τμημα δεσμευσης ψευδαργυρου
EA201291211A1 (ru) Фармацевтические композиции, содержащие гидроморфон и налоксон
EA201400623A1 (ru) Новые 2h-индазолы в качестве антагонистов рецептора ep
EA201201296A1 (ru) Способы лечения диабетических язв стопы
CY1116234T1 (el) Υποκατεστημενα 2-οξυ-κινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3